arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Tvardi Therapeutics, Inc.

TVRD
$1.88 ▲ +0.02 (+1.35%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
55 Visible periods
29 Metrics
Peer-ranked Benchmarks
Price Chart
29
Health
Poor
Bearish
auto_awesome

Analytical Summary

Tvardi Therapeutics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $17.6M
Dividend Yield
Revenue Growth None
Op. Margin None
ROIC -38.4%
FCF / Share $-0.62
Trailing P/E
Price / Book 1.2x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

55-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$2.57M
↑ +20.3%
Net Income Profit after all expenses
$-6.80M
↓ -38.7%
Operating Margin Operating profit as % of sales
-92.9%
↑ +60.4%
FCF / Share Free cash flow per share
$-0.62
↑ +79.7%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
11
Cash Quality
75

Dividend History

Dividend / share · sourced from SEC filings
$0.00 Latest / share

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 15 years · 55 quarters